Navigation Links
Cynosure's Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
Date:5/9/2008

WESTFORD, Mass., May 7 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced that it has received market approval from the Korea Food & Drug Administration (KFDA) for its flagship Accolade(TM) workstation for the removal of pigmented lesions.

Introduced in the first quarter of 2008, the Accolade is the third Cynosure flagship product approved for marketing in South Korea, following the Elite(TM) Aesthetic Workstation for laser hair removal and the Cynergy(TM) Workstation with MultiPlex(TM) Technology for the treatment of dermatological vascular conditions. All three workstations are being distributed in South Korea through Seoul-based OrientMG Ltd.

"As one of the world's major aesthetic markets, we believe South Korea represents a valuable growth opportunity for our products, and we are excited about the receipt of KFDA approval for our newest flagship product," said Cynosure President and Chief Executive Officer Michael Davin. "Due to the prevalence of dermal melanoses among Asian populations, South Korea is a primary target market for Accolade. We also are pursuing regulatory approval in other Asia Pacific countries, including China."

Accolade is a high-powered 755 nm, Q-switched Alexandrite laser for the removal of pigmented lesions. The unique combination of various spot sizes and the laser's high repetition rates allow for rapid treatment.

"With its power and precision, Accolade is well-suited for treating the full spectrum of benign pigmented lesions including Nevus of Ota, solar lentigenes, freckles and sun-damaged pigmentation," said Dr. Joon-hong Park of the Maymorning Clinic in Sungnam City, Kyunggi-Do, South Korea. "The accuracy of the aiming beam makes the Accolade easy to handle- treatment is delivered with specificity, minimizing side effects to the surrounding tissue and maximizing patient comfort."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.

Safe Harbor

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

Contact:

Scott Solomon

Vice President

Sharon Merrill Associates, Inc.

617.542.5300

cyno@investorrelations.com


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Keeneland Scales Eklin Digital Repository(TM) to 32 Medical Image Review Workstations
2. 6-month follow-up diagnostic mammograms recommended for women with probably benign lesions
3. Biomarker Spots Which Lesions Likely to Progress to Prostate Cancer
4. Melanoma lurks in larger skin lesions, NYU researchers find
5. Larger Skin Lesions More Likely to Be Melanoma
6. Larger skin lesions appear more likely to be melanomas
7. Mammography plus sonography can help rule out breast cancer in patients with palpable lesions
8. Topical Cream Treats Precancerous Lesions of Vulva
9. Small Brain Lesions More Common Than Thought in Those Over 60
10. Colonoscopy used to identify and remove flat colon lesions
11. Colonoscopy Used to Identify and Remove Flat Colon Lesions: Flat Colon Lesions More Common and More Likely to Be Cancer According to JAMA Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology: